Literature DB >> 18571079

Outbreak of diffuse lamellar keratitis caused by marking-pen toxicity.

Osmond Bruce Hadden1, Charles N J McGhee, Antony Trevor Morris, Trevor Buchanan Gray, Charles Peter Ring, Adam Stewart John Watson.   

Abstract

PURPOSE: To examine the evidence that a series of cases of diffuse lamellar keratitis (DLK) after laser in situ keratomileusis (LASIK) was caused by a type of marker pen.
SETTING: Eye Institute, Auckland, New Zealand.
METHODS: During a 10-week period, 522 consecutive LASIK procedures were performed using a 60 Hz IntraLase femtosecond laser (IntraLase Corp.) to create the LASIK flap and a 217Z 100 Hz excimer laser (Bausch & Lomb) to perform the refractive ablation. As standard practice, a marking pen was used to enable accurate flap realignment. Three weeks after a sudden increase in the incidence of DLK was identified, one of the 5 surgeons performed 5 consecutive bilateral cases using the marking pen in the right eyes but not in the left eyes.
RESULTS: Of the 522 LASIK cases (119 without marking pen, 403 with marking pen), DLK developed in 49 (9.4%). No eye treated without the marking pen developed DLK; of those in which the marking pen was used, 49 (12.2%) developed DLK (P<0.0001, Fischer exact test; odds ratio, 27). In the 5 consecutive bilateral cases in which the marking pen was used in the right eye but not the left eye, 4 right eyes and no left eye developed DLK (P=0.03). Forty-five of the 49 eyes with DLK quickly recovered. The other 4 developed central toxic keratopathy.
CONCLUSION: There is strong statistical evidence that the marking pen was a factor in the occurrence of DLK.

Entities:  

Mesh:

Year:  2008        PMID: 18571079     DOI: 10.1016/j.jcrs.2008.03.024

Source DB:  PubMed          Journal:  J Cataract Refract Surg        ISSN: 0886-3350            Impact factor:   3.351


  9 in total

1.  Bilateral central toxic keratopathy after laser in situ keratomileusis.

Authors:  Ahmed Abdelmaksoud; Nigel Terk-Howe Khoo; Hala Hanoot; Osama Ibrahim
Journal:  BMJ Case Rep       Date:  2015-11-30

2.  Diffuse lamellar keratitis after laser in situ keratomileusis with femtosecond laser flap creation.

Authors:  Fernando H de Paula; Christian G Khairallah; Leslie M Niziol; David C Musch; Roni M Shtein
Journal:  J Cataract Refract Surg       Date:  2012-04-08       Impact factor: 3.351

3.  Viscoelastic-Induced Interlamellar Stromal Keratopathy (VISK) during Cataract Surgery in a Patient with a History of Laser in situ Keratomileusis.

Authors:  Matthew Chang; Rosalind C Vo; Stewart Bernard; Stephanie Hoatson; Julio Narvaez
Journal:  Case Rep Ophthalmol       Date:  2022-03-17

4.  [Results of 308 consecutive femtosecond laser cuts for LASIK].

Authors:  T Kohnen; O K Klaproth; V Derhartunian; D Kook
Journal:  Ophthalmologe       Date:  2010-05       Impact factor: 1.059

5.  What is Central Toxic Keratopathy Syndrome if it is not Diffuse lamellar Keratitis Grade IV?

Authors:  Ribhi Hazin; Yassine J Daoud; Yousuf M Khalifa
Journal:  Middle East Afr J Ophthalmol       Date:  2010-01

6.  Incidence of diffuse lamellar keratitis after LASIK with 15 KHz, 30 KHz, and 60 KHz femtosecond laser flap creation.

Authors:  Christina H Choe; Carly Guss; David C Musch; Leslie M Niziol; Roni M Shtein
Journal:  J Cataract Refract Surg       Date:  2010-11       Impact factor: 3.351

7.  High-resolution optical coherence tomography visualization of LASIK flap displacement.

Authors:  Camila Haydée Rosas Salaroli; Yan Li; David Huang
Journal:  J Cataract Refract Surg       Date:  2009-09       Impact factor: 3.351

8.  Atypical presentation of acanthamoeba keratitis resembling central toxic keratopathy.

Authors:  Mathew S Ward; Jordan P Hastings; Kathryn M Shmunes; Yasmyne Ronquillo; Phillip C Hoopes; Majid Moshirfar
Journal:  Am J Ophthalmol Case Rep       Date:  2021-12-16

9.  Comparison of DLK incidence after laser in situ keratomileusis associated with two femtosecond lasers: Femto LDV and IntraLase FS60.

Authors:  Minoru Tomita; Yuko Sotoyama; Satoshi Yukawa; Tadayuki Nakamura
Journal:  Clin Ophthalmol       Date:  2013-07-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.